Support our Foundation of Myology project
1722 news items
Treatments and diagnosis for rare diseases: crucial issues
On 17/02/2023
The availability of treatments and the end of diagnostic delays are major challenges for people with rare diseases. AFM-Telethon and the actors of the Rare…
Muscle imaging as an assessment methodology in OPMD
On 17/02/2023
Canadian researchers have developed a whole-body magnetic resonance imaging protocol to aid diagnosis and study the natural history of the disease in ten patients with…
Clinical gender differences in FKRP-related LGMDR9
On 17/02/2023
Using four patient registries, one study was able to identify all patients (153) in Norway with genetically confirmed FKRP-related LGMD R9. The estimated disease prevalence…
Current innovative treatments for SMN1-related proximal spinal muscular atrophy in adults
On 16/02/2023
Prof. Cintas of the Toulouse Neuromuscular Reference Centre published in December 2022 a review of new therapies for SMN1-related proximal spinal muscular atrophy (SMA) in…
Retinal anomalies in inflammatory myopathies are frequent and should not be overlooked
On 16/02/2023
Indian and British researchers studied these phenomena by subjecting the patient cohort named MyoCite to a battery of ophthalmological tests. 43 adults with inflammatory myopathy,…
ERN EURO-NMD webinar, Feb. 16th – Stéphane Vassilopoulos (France)
On 15/02/2023
Caveolae and Bin1 form ring-shaped platforms for T-tubule initiation 16 February 2023 – 16:00 Paris time Stéphane Vassilopoulos (Myology Centre for Research, Institute of Myology, France)…
Constipation in SMA type I can be controlled with the right diet
On 15/02/2023
British clinicians conducted a clinical trial of a diet rich in amino acids and probiotics in 14 children with type I spinal muscular atrophy. To…
Beneficial effects of tamoxifen on muscle strength in mouse models of centronuclear myopathies
On 15/02/2023
A team from Strasbourg, supported by the AFM-Telethon, has studied the repositioning of tamoxifen in centronuclear myopathy (CNM), a drug which has already shown its…
Cases of inflammatory myopathy with coexisting myositis-specific antibodies
On 14/02/2023
Researchers in Taiwan have focused on the rare cases of inflammatory myopathy in which the myositis specific autoantibody (MSA) assay was positive in at least…
Nusinersen has differentiated neurometabolic effects depending on the severity of the SMA
On 14/02/2023
An Italian-American consortium of researchers studied the cerebrospinal fluid (CSF) of patients with spinal muscular atrophy (SMA) treated with intrathecal injections of nusinersen (Spinraza®) in…
First “Muscle Week”, 1-7 June 2023
On 13/02/2023
The Institute of Myology and AFM-Telethon organised a press conference on 7 February to position muscle as a public health issue by announcing the project…
First « Muscle Conferences » on 1 June at the Economic, Social and Environmental Council
On 13/02/2023
The Institute of Myology and AFM-Telethon organised a press conference on 7 February to promote muscle as a public health issue by announcing the project…
FOP : une tendance à l’efficacité du palovarotène
On 13/02/2023
Forty people with fibrodysplasia ossificans progressiva (FOP), aged 7 to 53 years, participated in the phase II trial of palovarotene, a selective gamma retinoic acid…
Standards now available for muscle fibre size and type during growth
On 13/02/2023
The evolution of muscle fibre morphometry during growth is poorly understood. French researchers and engineers involving scientists from the Institute of Myology have used a…
How to reconcile vaccination schedule and gene therapy in infants with SMA?
On 13/02/2023
Gene therapy has become a treatment option for many infants with severe forms of spinal muscular atrophy (SMA) and tomorrow for those diagnosed at a…
HDAC6 inhibition improves the phenotype of mdx mice
On 10/02/2023
Laurent Schaeffer’s team in Lyon, in collaboration with a Canadian team in Ottawa, has shown that inhibition of cytoplasmic histone deacetylase 6 (HDAC6) by administration…
The induction of self-tolerance is back on the agenda in myasthenia gravis
On 09/02/2023
According to preclinical work by Spanish researchers, carried out with the help of Rozen Le Panse’s team at the Institute of Myology : intraperitoneal injection…
First enzyme replacement therapy started in utero shows promise in Pompe disease
On 09/02/2023
A foetus with Pompe’s disease received ultrasound monitored alglucosidase alfa every 2 weeks from 24 to 34 weeks of pregnancy (6 injections). This baby girl…
« Muscle is a real public health issue and should be recognised as such » – Interview with Laurence Tiennot-Herment
On 07/02/2023
Interview with Laurence Tiennot-Herment, President of AFM-Telethon and Institute of Myology Association. Why is muscle a public health issue? As patients with neuromuscular diseases know all…
Muscle, a major public health issue
On 07/02/2023
Because muscles are a major public health issue, AFM-Telethon and the Institute of Myology, an international center of expertise on muscles and their diseases, are…
